Olmesartan medoxomil is an effective sartan with unique additional effects: a review of the evidence base

Abstract

Poorly controlled hypertension has been shown to be an independent risk factor for cardiovascular disease, stroke, renal failure, and increased mortality. Angiotensin II receptor blockers (ARBs) are one of five classes of drugs for the treatment of hypertension that have proven their effectiveness, safety, and have additional organoprotective effects. Among other ARBs, olmesartan medoxomil (OLM) has unique features of molecular structure and provides additional effects. More pronounced antihypertensive activity of OLM, stability of antihypertensive effect during the day, pleiotropic effects and a good tolerability profile in comparison with both representatives of other classes of antihypertensive medications and other ARBs have been proven in numerous clinical studies. According to the 2018 European Society of Cardiology Guidelines, fixed double (Olmetec Plus, Sevikar) and triple combinations (Sevikar HCT) based on OLM are indicated for most patients with hypertension due to better long-term adherence to therapy and increased normalization of blood pressure.